Scynexisincis A Biotechnology Company Focused On Developing Innovative Therapies For Challenging And Life Threatening Infectionsfounded In 1999 And Now Headquartered In Jersey Citynew Jerseyscynexis Has A Strong Background In The Life Scienceswith A Team Experienced In Creating Over 30 Medicines Across Various Therapeutic Areas The Company Specializes In Anti Infective Therapiesparticularly For Serious Fungal Infectionsscynexis Is Known For Its Key Productbrexafemmeibrexafungerp Which Was Approved By The Fda In 2019 For Treating Vulvovaginal Candidiasisthis Drug Is Part Of A New Class Of Antifungal Agents And Is Being Investigated For Additional Usesincluding Invasive Candidiasis And Invasive Aspergillosisanother Product In Development Is Scy 247Targeting Drug Resistant Fungal Infections Like Candida Aurisin 2023Scynexis Was Acquired By Glaxosmithklineenhancing Its Position In The Anti Infectives Market
